Funding opportunity
BioMedPartners has announced the first closing of BioMedInvest II, its second venture capital fund, at CHF 95 million (€64.4 million). The fund will invest in early to mid-stage companies in Switzerland, Germany and neighbouring countries of the European Union.
With this closing, BioMedPartners, founded in 2003, has raised a total of over CHF 240 million (€169.6 million). The new fund, BioMedInvest II, will be dedicated to investing in healthcare companies that have the potential to do a large deal with, or be bought by, pharmaceutical companies looking to fill their product pipelines.
The fund is backed by both existing and new investors, including lead investor ERP-EIF Dachfonds. The fund will remain open to additional new investors for some months.
“Up to now, BioMedPartners has invested in more than 25 companies and created a track record of successful exits through IPOs and trade sales, including the trade sale of Glycart Biotechnology AG to Roche,” said Andrea Pfeifer, Chairman of BioMedInvest I.
“The fact that BioMedPartners was able to raise a new early-stage fund in such turbulent times encourages the management team to continue with its favourable business model of investing in promising early-stage healthcare companies in Europe and actively supporting companies in their business/corporate development.”
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
